|
|
Hepatitis C patients tend to develop liver cancer: Taiwan researcher
|
Hepatitis C raises risk of liver cancer, expert warns
|
Hepatitis C patients tend to develop liver cancer: researcher
|
Hepatitis B hasn't gone away - and may come back
|
Research from France, Japan and the United States broadens understanding of hepatitis C virus
|
Institute Pasteur, France, researchers summarize new study results
|
Research from Rockefeller University, U.S., provides new hepatitis C virus data
|
for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
|
Recent findings from Pusan National University, Department of Molecular Biology highlight research in hepatitis B virus
|
Studies from National Taiwan University, Taiwan, yield new information about hepatitis B virus
|
Researchers' work from Wuhan University, College of Life Science focuses on hepatitis B virus epidemiology
|
Researchers in France, Italy and the Netherlands zero in on hepatitis C virus
|
Recent studies from Osaka University add new data to hepatitis C virus therapy
|
Officials from GlaxoSmithKline report details of recent activities
|
Headline Maker: Human Genome Sciences Reports Positive Final Results Of Phase 2b Trial of Albuferon(R)
|
for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
|
Government-Owned Inventions; Availability for Licensing
|
Government-Owned Inventions; Availability for Licensing
|
PEGASYS(R) Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered ''Cured''
|
Data Suggest that PEGASYS(R) May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron(R)
|
